UBS Group’s 60 Degrees Pharmaceuticals Warrant SXTPW Stock Holding History

UBS Group’s Portfolio SXTPW Stock Details SXTPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20	Sell	647 -55	-8%	-$3	﹤0.01%	10275
2026 Q1	$35	Sell	702 -86	-11%	-$6	﹤0.01%	10241
2025 Q4	$50	Sell	788 -26	-3%	-$1	﹤0.01%	10272
2025 Q3	$30	Sell	814 -687	-46%	-$47	﹤0.01%	10078
2025 Q2	$62	Buy	+1,501	New	+$77	﹤0.01%	10041
2025 Q1	–	Sell	-506	Closed	-$15	–	10710
2024 Q4	$15	Buy	506 +426	+533%	+$12	﹤0.01%	9793
2024 Q3	$3	Buy	+80	New	+$5	﹤0.01%	9404
2024 Q2	–	Sell	-248	Closed	-$19	–	10073
2024 Q1	$19	Buy	248 +148	+148%	+$12	﹤0.01%	9040
2023 Q4	$4	Sell	100 -5,965	-98%	-$755	﹤0.01%	9167
2023 Q3	$2.12K	Buy	+6,065	New	+$2.6K	﹤0.01%	7762

Other funds holding SXTPW

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Torno Capital Cohasset, Massachusetts $3.47B AUM 37.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group's SXTPW Position: Q2 2026 in Review

UBS Group reduced its 60 Degrees Pharmaceuticals Warrant (SXTPW) stake by 7.8% in Q2 2026, selling an estimated $3 and leaving 647 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #10275.

UBS Group first reported a position in SXTPW in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.12K in Q3 2023. 5 funds tracked by Wall St. Rank hold SXTPW as of Q2 2026.

UBS Group held 647 shares of 60 Degrees Pharmaceuticals Warrant worth $20 as of Q2 2026.
UBS Group sold 55 60 Degrees Pharmaceuticals Warrant shares in Q2 2026, an estimated $3.
60 Degrees Pharmaceuticals Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10275 holding.
UBS Group first reported a position in 60 Degrees Pharmaceuticals Warrant in Q3 2023 and has held it in 10 quarters since.
UBS Group's 60 Degrees Pharmaceuticals Warrant position peaked at $2.12K in Q3 2023.
5 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.